Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Felezonexor (SL-801) in advanced solid tumors
NCT02667873Phase 1Completed
- Sponsor
- Stemline Therapeutics
- Start
- Feb 2016
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of felezonexor in solid tumor, sponsored by Stemline Therapeutics. Primary endpoints: Percentage of patients experiencing treatment-related and treatment-emergent adverse events up to 5 years and Maximum Tolerated Dose up to 5 years. Started Feb 2016; status: completed.
02
Drugs
felezonexor
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02667873.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02667873.